Neurocrine Biosciences (NBIX) Price to Earnings (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Price to Earnings for 17 consecutive years, with 118.58 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Earnings rose 2.45% year-over-year to 118.58; the trailing twelve-month figure through Jun 2026 stood at 24.27 (down 32.06% YoY), and the FY2025 full-year result was 29.66, down 25.38% from the prior year.
• Price to Earnings rose to 118.58 in Q2 2026 per NBIX's latest filing, from 66.97 in the prior quarter.
• Across five years, Price to Earnings topped out at 1386.0 in Q1 2025 and bottomed at 551.43 in Q2 2022.
• Historically, Price to Earnings has averaged 175.61 across 5 years, with a median of 117.17 in 2026.
• The sharpest annual moves came in 2022 and 2024: Price to Earnings plunged 353.36% in 2022, then surged 348.14% in 2024.
• Over 5 years, Price to Earnings stood at 129.51 in 2022, then plunged by 32.01% to 88.05 in 2023, then jumped by 49.47% to 131.6 in 2024, then fell by 29.81% to 92.37 in 2025, then advanced by 28.38% to 118.58 in 2026.
• According to Business Quant data, Price to Earnings over the past three periods registered 118.58, 66.97, and 92.37 for Q2 2026, Q1 2026, and Q4 2025 respectively.